SCHEMBL2266733

SCHEMBL2266733

COc1ccc2c(ccn2C(=O)OC(C)(C)C)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB1 Q9H4B7 1/20 0.55
TFPI2 P48307 1/20 0.49
PIK3CD O00329 2/20 0.45
ABL1 P00519 2/20 0.45
EGFR P00533 2/20 0.45
HCK P08631 2/20 0.45
SRC P12931 2/20 0.45
KDR P35968 2/20 0.45
PIK3CA P42336 2/20 0.45
PIK3CB P42338 2/20 0.45
MTOR P42345 2/20 0.45
PIK3CG P48736 2/20 0.45
EPHB4 P54760 2/20 0.45
PRKDC P78527 2/20 0.45
PI4KB Q9UBF8 2/20 0.45
MTNR1A P48039 1/20 0.45
MTNR1B P49286 1/20 0.45
FABP4 P15090 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
ALDH1A1 P00352 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30230816 1.00 TUBB1 (0.55) TUBB1TFPI2PIK3CDABL1EGFR
SCHEMBL982760 0.89 TFPI2 (0.49) TUBB1TFPI2MTNR1AMTNR1BFABP4
SCHEMBL29992081 0.86 PIK3CD (0.44) TUBB1TFPI2PIK3CDABL1EGFR
SCHEMBL1372514 0.86 ELANE (0.47) TUBB1TFPI2PIK3CDABL1EGFR
SCHEMBL17061440 0.86 PIK3CD (0.44) TUBB1TFPI2PIK3CDABL1EGFR
SCHEMBL3839289 0.86 TFPI2 (0.51) TUBB1TFPI2PIK3CDABL1EGFR
SCHEMBL13247869 0.86 PIK3CG (0.47) TUBB1PIK3CDABL1EGFRHCK
SCHEMBL7988808 0.85 TUBB1 (0.60) TUBB1TFPI2MTNR1AMTNR1BFABP4
SCHEMBL2720556 0.85 KCNQ3 (0.47) TUBB1TFPI2PIK3CDABL1EGFR
SCHEMBL28683537 0.84 TUBB1 (0.59) TUBB1TFPI2MTNR1AMTNR1BFABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115398219-B Capillary gel electrophoresis and its use in complex biomolecules 阿瑞斯贸易股份公司 2025-04-01 CN disclosed
US-20240254081-A1 CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS KARE CHEMICAL TECHNOLOGIES INC. (CA) 2024-08-01 US disclosed
EP-4133263-B1 CAPILLARY GEL ELECTROPHORESIS AND ITS USE WITH COMPLEX BIOLOGICAL MOLECULES ARES TRADING SA (CH) 2024-05-22 EP disclosed
EP-4334285-A1 CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS Kare Chemical Technologies Inc. (CA) 2024-03-13 EP disclosed
CN-117597329-A Method for the catalytic synthesis of tryptamine and precursors thereof 凯尔化学科技公司 2024-02-23 CN disclosed
US-11664093-B2 Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2023-05-30 US disclosed
US-20230152275-A1 CAPILLARY GEL ELECTROPHORESIS AND ITS USE WITH COMPLEX BIOLOGICAL MOLECULES ARES TRADING S.A. (CH) 2023-05-18 US disclosed
EP-4133263-A1 CAPILLARY GEL ELECTROPHORESIS AND ITS USE WITH COMPLEX BIOLOGICAL MOLECULES Ares Trading S.A. (CH) 2023-02-15 EP disclosed
CN-115398219-A Capillary gel electrophoresis and its use in complex biomolecules 阿瑞斯贸易股份公司 2022-11-25 CN disclosed
WO-2022232931-A1 CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS KARE CHEMICAL TECHNOLOGIES INC. (CA) 2022-11-10 WO disclosed
WO-2011092293-A2 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2011-08-04 WO disclosed
US-20100144726-A1 NOVEL INDOLIC DERIVATIVES, THEIR PREPARATION PROCESSES AND THEIR USES IN PARTICULAR AS ANTIBACTERIALS UNIVERSITE JOSEPH FOURIER (FR) 2010-06-10 US disclosed
EP-1276720-B1 2-ACYL INDOL DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS BAXTER HEALTHCARE SA (CH) 2006-12-20 EP disclosed
EP-1442015-A1 USE OF 2-ACYLINDOLES IN THE TREATMENT OF TUMORS Baxter Healthcare SA (CH) 2004-08-04 EP disclosed
US-20030158216-A1 2-acyl indole derivatives and their use as antitumor agents BAXTER ONCOLOGY GMBH 2003-08-21 US disclosed
WO-2003037861-A1 USE OF 2-ACYLINDOLES IN THE TREATMENT OF TUMORS BAXTER HEALTHCARE SA (CH) 2003-05-08 WO disclosed
EP-1276720-A2 2-ACYL INDOL DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS ASTA Medica AG (DE) 2003-01-22 EP disclosed
US-20020091124-A1 2-acyl indole derivatives and their use as antitumor agents BECKERS THOMAS (DE) 2002-07-11 US disclosed
CN-1331674-A Sulfonamide hydroxamates HOFFMANN LA ROCHE (CH) 2002-01-16 CN disclosed
WO-2001082909-A2 2-ACYL INDOL DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS BAXTER HEALTHCARE SA (DE) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254081-A1 CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS HNMT, TPSB2, TPSG1 TUBB1 2205/4885TFPI2 555/4885PIK3CD 3971/4885
US-20030158216-A1 2-acyl indole derivatives and their use as antitumor agents IDO1, IDO2, INMT TUBB1 62/4885TFPI2 363/4885PIK3CD 1422/4885
US-20020091124-A1 2-acyl indole derivatives and their use as antitumor agents IDO1, IDO2, INMT TUBB1 62/4885TFPI2 363/4885PIK3CD 1422/4885
US-20100144726-A1 NOVEL INDOLIC DERIVATIVES, THEIR PREPARATION PROCESSES AND THEIR USES IN PARTICULAR AS ANTIBACTERIALS GPBAR1, TPH1, GPER1 TUBB1 1252/4885TFPI2 3450/4885PIK3CD 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.